Paths to the patient: Business models for drug discovery and development
Samen met hollandbio, Van derden03/06/25
How do you choose the right path to bring your drug discovery to patients? That’s the key question during ‘Paths to the Patient’!
Join Johnson & Johnson’s upcoming program as they bring together experts who have successfully traveled these paths and are ready to share insights into various development routes. This program specifically targets early innovators and start-ups looking to bring their drug to patients. Topics include academic-industry partnerships, IP strategies, spin-off creation, funding, and more.
Where local considerations are essential, the speakers will focus on the Dutch life sciences ecosystem, while most insights will have universal relevance. See the full programme below.
Programme
13:00 | Visitor registration opens, In-person attendees only
13:30 | General introduction: Tess Korthout, Early Innovation Partner Benelux, Johnson & Johnson
13:45 | Current state of biotech: Wieteke Wouters, Program Director, hollandbio
14:05 |Next steps after discovery
Four short presentations followed by a panel discussion and Q&A.
- Nettie Buitelaar, CEO, Biotech Booster
- Jeroen Blokhuis, Head of Valorisation, Oncode Institute
- Trudy Straetemans, Lead, DARE-NL & Associate Professor Translational Tumor Immunology, UMC Utrecht*
- Elmer Maurits, CEO/Co-Founder, iProtics
- Paul Korte, Director External Affairs, Johnson & Johnson, and Board Member, FAST (moderator)
15:15 | Break
15:45 | Next steps for start-ups
Four short presentations followed by a panel discussion and Q&A.
- Jan-Jaap Verhoef, Founder, Imuno Therapeutics
- Maarten Ligtenberg, CEO and Co-Founder, Flindr Therapeutics*
- Lilian Alcaraz, VP Early Innovation Partnering EMEA, Johnson & Johnson
- Margien Boels, Investment Manager, FIRST fund, BioGeneration Ventures
- Non-dilutive funding expert speaker to be announced
- Nettie Buitelaar, CEO, Biotech Booster (Moderator)
16:55 | Closing remarks
17:00 | Informal Q&A
18:00 | Close
Registration
Start-ups, early innovators, and entrepreneurs are welcome to register here. Stakeholders supporting these start-ups are also welcome to join.